-
Soo-Kyung ChoHanyang Univ.Korea
-
Dr. Cho obtained her medical degree from Inje University and completed a five-year internship and residency at Inje University Hospital in Busan, Korea. She then pursued specialized training in rheumatology and clinical epidemiology at Hanyang University Hospital for Rheumatic Diseases (HUHRD) in Seoul, Korea.
Following this, Dr. Cho served as a research professor at the Clinical Research Center for Rheumatoid Arthritis (CRCRA), funded by the Ministry of Health and Welfare, Korea. In this role, she played a pivotal part in establishing the KORean Observational Study Network for Arthritis (KORONA) project, the first Korean multicenter prospective cohort for rheumatoid arthritis (RA) patients. Through KORONA, Dr. Cho has conducted extensive outcomes research and comparative effectiveness studies to improve the understanding and management of RA.
From September 2011 to August 2012, Dr. Cho was a research associate in the Department of Pharmacovigilance at Tokyo Medical and Dental University, Japan. Upon returning to Korea in 2012, she was appointed Assistant Professor in the Department of Internal Medicine at Hanyang University. Later, from September 2018 to August 2019, she furthered her expertise in pharmacoepidemiology and pharmacoeconomics as a visiting professor at the Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Harvard Medical School, USA.
Currently, Dr. Cho is a professor and clinician in the Department of Rheumatology and the Section of Pharmacoepidemiology at HUHRD.
Dr. Cho’s research interests in rheumatology are broad, with a focus on clinical epidemiologic studies utilizing disease-specific cohorts and national claims databases. Since 2011, her work has centered on evaluating the effectiveness and safety of biologic agents and anti-rheumatic drugs, contributing significantly to the advancement of knowledge and care in rheumatic diseases.
| Date | Time | Room | Session Title | Lecture Title |
|---|---|---|---|---|
| May 16 | 16:30-17:00 | Room 1 (3F) | International Symposium 4_Optimizing Treatment Strategies to Mitigate Cardiovascular Risk in Rheumatoid Arthritis Patients | Current evidence on JAK inhibitors and cardiovascular risk in Korean rheumatoid arthritis patients |
